Robert Brenner Sells 2,151 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider Robert Brenner sold 2,151 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $90,298.98. Following the sale, the insider directly owned 50,947 shares in the company, valued at approximately $2,138,755.06. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Vera Therapeutics Stock Up 1.6%

VERA stock opened at $42.35 on Friday. The company has a market cap of $2.97 billion, a PE ratio of -10.61 and a beta of 1.16. The business has a 50-day simple moving average of $46.53 and a 200 day simple moving average of $35.35. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $56.05. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the previous year, the business posted ($0.72) EPS. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

More Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: FDA priority review and NEJM/ASN recognition for atacicept — Vera reported positive Phase 3 ORIGIN‑3 data for atacicept in IgA nephropathy that were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA has granted priority review for the atacicept BLA with a PDUFA date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid‑2026. Management also said recent 2025 equity and debt financings leave the company well‑capitalized into and beyond approval and launch. Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
• Neutral Sentiment: Financials/earnings update — Vera released FY‑2025 results and quarterly EPS figures; one report shows EPS of ($1.39) for the quarter (slightly missing consensus by ~$0.05). The results highlight continued operating losses but the company emphasizes runway provided by recent financings. Investors will focus on how close the company is to commercialization economics once/if atacicept is approved. View Press Release
• Negative Sentiment: Concentrated insider selling — multiple senior executives (including the CEO, CFO, COO and other officers) sold shares on Feb 23 at roughly $42/share (CEO Marshall Fordyce sold ~16,925 shares; other officers also reduced holdings). Such clustered insider sales can prompt investor caution and short‑term selling pressure despite the regulatory progress. Vera Therapeutics Insider Sells

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VERA. Virtu Financial LLC acquired a new position in Vera Therapeutics in the 4th quarter worth about $297,000. Invesco Ltd. increased its stake in shares of Vera Therapeutics by 193.3% in the fourth quarter. Invesco Ltd. now owns 89,851 shares of the company’s stock valued at $4,550,000 after buying an additional 59,219 shares during the period. KVP Capital Advisors LP bought a new position in Vera Therapeutics in the 4th quarter valued at approximately $1,656,000. XTX Topco Ltd acquired a new stake in Vera Therapeutics during the 4th quarter worth approximately $508,000. Finally, Virtus Investment Advisers LLC grew its holdings in Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after acquiring an additional 290 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. The Goldman Sachs Group upped their target price on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Pivotal Research set a $73.00 price target on Vera Therapeutics in a report on Friday, December 5th. JPMorgan Chase & Co. dropped their price objective on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Finally, Bank of America boosted their target price on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Vera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $78.80.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.